Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Thrombosis, and Fibrosis Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PDI/P4HB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human P4HB / PDI Protein (Full Length & Active Site Mutants) Purity: >95% by SDS-PAGE. Host: HEK293 (Native Glycosylation) or E. coli. Endotoxin: <1.0 EU/μg. Sequence Verified. |
View P4HB Products |
| Gene Delivery | P4HB Promise-ORF / Lentivirus Particles Full-length human P4HB ORF for stable cell line generation and overexpression validation. |
View P4HB Products |
| Benchmark Ab | Anti-P4HB Recombinant Monoclonal Antibody Recombinant positive control derived from benchmark clone RL90 for flow cytometry, Western Blot, and ELISA. |
View P4HB Products |
| Validator | P4HB siRNA Set Target-specific siRNA pool for target knockdown and phenotypic assay validation. |
View P4HB Products |
| Related Target A | PDIA3 (ERp57) Homologous disulfide isomerase. Crucial for selectivity counter-screening to avoid off-target toxicity. |
View PDIA3 Products |
| Related Target B | PDIA4 (ERP72) PDI family member upregulated in chemoresistant tumors. Target for dual-inhibitor screening. |
View PDIA4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Cross-Reactivity | High-purity recombinant PDIA3 and PDIA4 proteins available for robust counter-screening panels. |
| Enzymatic Assay Interference | Sequence-verified wild-type and active-site mutant (CGHC to SGHS) proteins to distinguish true catalytic inhibition from non-specific binding. |
| Lack of Validated Controls | Sequence-defined recombinant benchmark antibodies (clone RL90) provided as reliable positive controls. |
| In Vitro Knockdown Verification | Pre-designed siRNA pools to confirm target specificity in disease-relevant cell lines. |
Live PDI/P4HB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PDI/P4HB therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum alkylating agents to highly selective small-molecule inhibitors and cell-surface targeting monoclonal antibodies. As first-generation pan-PDI inhibitors reach clinical and preclinical evaluation, the next wave of R&D is targeting specific PDI conformations and localized cell-surface populations to mitigate systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Glioblastoma, Multiple Myeloma, Thrombosis | Enzymatic Activity Assays (Requires active recombinant P4HB and mutant controls) |
| Monoclonal Antibodies | Clinical-Stage Biopharma | Thrombotic Disorders, Solid Tumors | Cell-surface binding assays (Requires Lentivirus for stable cell line construction) |
| Combination Therapies | Oncology Consortia | Chemoresistant Cancers | Synergy validation assays (Requires target-specific siRNA knockdown controls) |